Le Lézard
Classified in: Covid-19 virus
Subject: LAW

Class Certified in Action Against The University of South Florida Board of Trustees


MIAMI, Sept. 27, 2023 /PRNewswire/ -- The Moskowitz Law Firm is leading an action on behalf of all students who were enrolled during the Spring 2020, Summer 2020, Fall 2020, and Spring 2021 academic semesters at USF. Attorney Adam Moskowitz points out that "Millions of dollars were collected from students by USF, for specific and itemized services (like health center, athletics and transportation?fees) that were admittedly never provided." The lawsuit entitled Moore v. The University of South Florida Board of Trustees, Case No.: 21-CA-2445 (Division L) is currently pending in Circuit Court in Hillsborough County, Florida.

On August 14, 2023, the Court entered an Order certifying a class of students enrolled at the University of South Florida who paid Fees for services, facilities, resources, activities, and/or events that were not provided. All students who were enrolled at the University of South Florida during the COVID-19 pandemic may be able to recoup fees for on-campus services they paid for but did not receive. According to a notice issued today, "The Plaintiff alleges that the University of South Florida ("USF") breached a contract when it charged and refused to refund fees she and other students paid for on-campus services that USF did not provide to any student during the Spring, Summer, and Fall 2020 academic semesters, and Spring 2021 academic semester, due to the closure of its campuses in response to the COVID-19 pandemic. Based on these allegations, Plaintiff asserts claims on behalf of herself and other USF students against USF for breach of contract." 

Students who want to be part of the lawsuit don't have to do anything except await the outcome. USF has appealed the decision. 

For more information, please visit: https://moskowitz-law.com/usf

SOURCE The Moskowitz Law Firm


These press releases may also interest you

at 08:15
Vir Biotechnology, Inc. today announced that its Phase 2 SOLSTICE clinical trial evaluating the safety, tolerability and efficacy of tobevibart and elebsiran for the treatment of people living with chronic hepatitis delta (CHD) virus has completed...

at 08:05
Aptevo Therapeutics Inc. , a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and...

at 08:00
CLS Holdings USA, Inc. , the ''Company'' or ''CLS'', a diversified cannabis company operating as Cannabis Life Sciences, is thrilled to announce its strategic partnership with SOMA, the leading innovator in solventless cannabis extraction...

at 08:00
In anticipation of International Women's Day and the collective pursuit of a more inclusive world for women, today, the UN Global Compact Network Canada released findings of a recent project that revealed crises are gendered. The "Accelerating...

at 08:00
YS Biopharma Co., Ltd. ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and...

at 07:35
Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today announced that the KARDIA-2 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the...



News published on and distributed by: